SG10201807318RA - Methods for treating chronic obstructive pulmonary disease using benralizumab - Google Patents

Methods for treating chronic obstructive pulmonary disease using benralizumab

Info

Publication number
SG10201807318RA
SG10201807318RA SG10201807318RA SG10201807318RA SG10201807318RA SG 10201807318R A SG10201807318R A SG 10201807318RA SG 10201807318R A SG10201807318R A SG 10201807318RA SG 10201807318R A SG10201807318R A SG 10201807318RA SG 10201807318R A SG10201807318R A SG 10201807318RA
Authority
SG
Singapore
Prior art keywords
benralizumab
methods
pulmonary disease
chronic obstructive
obstructive pulmonary
Prior art date
Application number
SG10201807318RA
Other languages
English (en)
Inventor
Der Merwe Rene Van
Christine Ward
Ubaldo Martin
Lorin Roskos
Bing Wang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG10201807318RA publication Critical patent/SG10201807318RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201807318RA 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab SG10201807318RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US201461970126P 2014-03-25 2014-03-25

Publications (1)

Publication Number Publication Date
SG10201807318RA true SG10201807318RA (en) 2018-09-27

Family

ID=52809872

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201807318RA SG10201807318RA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab
SG11201601807XA SG11201601807XA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201601807XA SG11201601807XA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Country Status (12)

Country Link
US (4) US20150104447A1 (https=)
EP (2) EP3485902A1 (https=)
JP (3) JP2016534996A (https=)
KR (1) KR20160061352A (https=)
CN (2) CN113230399A (https=)
AU (2) AU2014334563A1 (https=)
BR (1) BR112016008082A2 (https=)
CA (1) CA2925402A1 (https=)
MX (2) MX2016004329A (https=)
RU (1) RU2706729C2 (https=)
SG (2) SG10201807318RA (https=)
WO (1) WO2015057668A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
BR112022010934A2 (pt) * 2019-12-06 2022-11-29 Sanofi Biotechnology Métodos para tratar copd administrando um antagonista de il-33
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
HUE036885T2 (hu) * 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) * 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab

Also Published As

Publication number Publication date
AU2014334563A1 (en) 2016-04-07
SG11201601807XA (en) 2016-04-28
JP6870037B2 (ja) 2021-05-12
MX2016004329A (es) 2016-11-10
RU2016118425A3 (https=) 2018-07-19
KR20160061352A (ko) 2016-05-31
JP2016534996A (ja) 2016-11-10
MX2019013468A (es) 2020-02-12
JP2019203009A (ja) 2019-11-28
RU2706729C2 (ru) 2019-11-20
JP2021107421A (ja) 2021-07-29
CA2925402A1 (en) 2015-04-23
CN113230399A (zh) 2021-08-10
EP3057609A1 (en) 2016-08-24
US20180291108A1 (en) 2018-10-11
US20200123262A1 (en) 2020-04-23
RU2016118425A (ru) 2017-11-21
EP3485902A1 (en) 2019-05-22
CN105636607A (zh) 2016-06-01
US20150104447A1 (en) 2015-04-16
EP3057609A4 (en) 2017-03-22
BR112016008082A2 (pt) 2017-10-17
AU2020202333A1 (en) 2020-04-23
US20170107291A1 (en) 2017-04-20
WO2015057668A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
SG10201807318RA (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
PH12015501108A1 (en) Treatment of pulmonary disease
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
PH12015502075A1 (en) Treatment of cataplexy
AU2011328009A8 (en) Compounds and methods for treating pain
CA2897464C (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
EA201990684A1 (ru) Способы применения оксигенированных холестеролсульфатов (ocs)
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX368508B (es) Benralizumab para usarse en la reducción de la tasa de exacerbación de asma.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
MX2015006720A (es) D-metadona para el tratamiento de sintomas psiquiatricos.
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MX2016001384A (es) Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
EA201690446A1 (ru) Лечение множественной миеломы
UA74021U (ru) Способ лечения хронического вирусного гепатита с
HK1227729A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
UA55818U (ru) Способ лечения хронических заболеваний роговицы